Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “formulation”

865 pharma patents match "formulation" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 865
Index total 30,257
Page 4 / 37

Quick answer

This filtered view shows 865 pharmaceutical patents matching "formulation" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

865 results for “formulation” · 30,257 patents in full index Clear search

  1. US 12133914

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  2. US 12128092

    Lyophilized factor IX formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  3. US 12128109

    Muscle targeting complexes and formulations for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  4. US 12123035

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  5. US 12115149

    Formulations, methods, kits, and dosage forms

    MedRegen, LLC · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  6. US 12115255

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  7. US 12115254

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  8. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  9. US 12102671

    Method of vaccination with an attenuated RSV vaccine formulation

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  10. US 12104185

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  11. US 12102637

    Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Neurocrine Biosciences, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  12. US 12104184

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  13. US 12090139

    Formulations comprising triptan compounds

    Tonix Medicines, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  14. US 12091692

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  15. US 12083122

    Laureth-4 containing topical formulations

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  16. US 12083229

    Ocular drug delivery formulation

    INMED PHARMACEUTICALS INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  17. US 12083227

    Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Neurocrine Biosciences, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  18. US 12077502

    Formulations of T-type calcium channel modulators and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  19. US 12077593

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  20. US 12071516

    Polymeric stabilizing formulations

    Nano Precision Medical, Inc. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  21. US 12070502

    Process for reducing subvisible particles in a pharmaceutical formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  22. US 12064398

    Parenteral formulations

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  23. US 12064516

    Pharmaceutical formulations and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  24. US 12060590

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted